Japanese information technology company NEC has created CYTLIMIC, a company designed to develop and apply therapeutic cancer peptide vaccines manufactured using NEC’s artificial intelligence technology. NEC’s technology uses machine learning to develop “immune function prediction technology”, which can detect peptides for potential vaccines quickly and inexpensively. The tech has been used in research collaboration with Kochi University and Yamaguchi University to develop a vaccine that could be effective as a treatment for hepatoma and oesophageal cancer and is compatible with approximately 85% of Japanese citizens.
Japanese information technology company NEC has created CYTLIMIC, a company designed to develop and apply therapeutic cancer peptide vaccines manufactured using NEC’s artificial intelligence technology. NEC’s technology uses machine learning to develop “immune function prediction technology”, which can detect peptides for potential vaccines quickly and inexpensively. The tech has been used in research collaboration with Kochi University and Yamaguchi University to develop a vaccine that could be effective as a treatment for hepatoma and oesophageal cancer and is compatible with 85% of Japanese citizens.